晚期可切除直肠癌手术后同步放化疗的疗效分析

目的探讨晚期可切除直肠癌手术后进行同步放化疗的疗效。方法 80例晚期直肠癌患者根据治疗方法分为治疗组和对照组,每组40例。所有患者均行全直肠系膜切除术治疗,术后治疗组患者给予同步放化疗。结果两组患者术后切口感染、吻合口漏、肠梗阻等并发症发生率比较差异无统计学意义(P>0.05)。两组患者不良反应主要为乏力、恶心呕吐、腹泻和血小板减少等,组间差异无统计学意义(P>0.05)。治疗组和对照组的肿瘤浸润淋巴细胞(TIL)反应阳性率分别为75.0%和90.0%,差异有统计学意义(P<0.05)。随访12个月,治疗组与对照组的生存率分别为95.0%和75.0%,差异有统计学意义(P<0.05)。结论晚期可切除直肠癌术后同步放化疗的应用安全性好,可通过恢复机体的局部免疫功能来提高生存率,值得推广应用。

The efficacy of concurrent chemoradiotherapy for advanced resectable rectal cancer patients

Objective To investigate the concurrent chemoradiotherapy efficacy for advanced resectable rectal cancer. Methods 80 patients with advanced colorectal cancer were divided into the treatment group 40 cases） and control group （40 cases） according to treatment, all patients were given total mesorectal excision, and the treatment group received postoperative chemoradiotherapy. Results The incidence of postoperative wound infection, anastomotic leak, intestinal obstruction between the two groups had no significant difference （ P 〉 0. 05 ）. The major toxicities included fatigue, nausea, vomiting, diarrhea, throm- bocytopenia, etc. , but there were no significant differences （ P 〉 0. 05 ）. TIL-positive rates of the treatment group and the control group were 75.0% and 90. 0%, and there was significant differences between the groups （P 〈 0. 05 ）. After 12 months＇ follow-up, the survival rate of the treatment group （95.0%） was higher than that of the control group＇s （75.0% ,P 〈 0. 05）. Conclusions The concurrent chemoradiotherapy for advanced resectable rectal cancer is safe by restoring the body＇s immune function to improve survival, which deserves further application.